{"name": "Ceptaris Therapeutics",
 "permalink": "ceptaris-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/ceptaris-therapeutics",
 "homepage_url": "http://www.ceptaris.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2002,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "610-975-9290 ",
 "description": "",
 "created_at": "Wed Feb 22 04:04:36 UTC 2012",
 "updated_at": "Tue Apr 02 13:16:23 UTC 2013",
 "overview": "\u003Cp\u003ECeptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris\u0026#8217; investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       42],
      "assets/images/resized/0017/5338/175338v1-max-150x150.png"],
     [[250,
       70],
      "assets/images/resized/0017/5338/175338v1-max-250x250.png"],
     [[356,
       100],
      "assets/images/resized/0017/5338/175338v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman and CEO",
    "person":
     {"first_name": "Stephen",
      "last_name": "Tullman",
      "permalink": "stephen-tullman",
      "image": null}},
   {"is_past": false,
    "title": "COO \u0026 CFO",
    "person":
     {"first_name": "Doug",
      "last_name": "Gessl",
      "permalink": "doug-gessl",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$25M",
 "funding_rounds":
  [{"round_code": "debt_round",
    "source_url": "http://ceptaris.com/news/2012FEB21.asp",
    "source_description": "CEPTARIS SECURES $15M IN VENTURE DEBT FINANCING",
    "raised_amount": 15000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 2,
    "funded_day": 21,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Silicon Valley Bank",
         "permalink": "silicon-valley-bank-1",
         "image":
          {"available_sizes":
            [[[150,
               41],
              "assets/images/resized/0006/1420/61420v6-max-150x150.png"],
             [[250,
               69],
              "assets/images/resized/0006/1420/61420v6-max-250x250.png"],
             [[268,
               74],
              "assets/images/resized/0006/1420/61420v6-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Oxford Finance Corporation",
         "permalink": "oxford-finance-corporation",
         "image":
          {"available_sizes":
            [[[114,
               150],
              "assets/images/resized/0006/0701/60701v2-max-150x150.jpg"],
             [[175,
               229],
              "assets/images/resized/0006/0701/60701v2-max-250x250.jpg"],
             [[175,
               229],
              "assets/images/resized/0006/0701/60701v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "d",
    "source_url": "http://www.finsmes.com/2012/06/ceptaris-therapeutics-raises-10m-series-d-1-funding.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Ceptaris Therapeutics Raises $10M in Series D-1 Funding",
    "raised_amount": 10000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 6,
    "funded_day": 5,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Vivo Ventures",
         "permalink": "vivo-ventures",
         "image":
          {"available_sizes":
            [[[150,
               62],
              "assets/images/resized/0004/6854/46854v1-max-150x150.png"],
             [[200,
               83],
              "assets/images/resized/0004/6854/46854v1-max-250x250.png"],
             [[200,
               83],
              "assets/images/resized/0004/6854/46854v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Palo Alto Investors",
         "permalink": "palo-alto-investors",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0001/9366/19366v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0001/9366/19366v2-max-250x250.png"],
             [[288,
               42],
              "assets/images/resized/0001/9366/19366v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Burrill \u0026 Company",
         "permalink": "burrill-co",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0402/50402v1-max-150x150.png"],
             [[250,
               43],
              "assets/images/resized/0005/0402/50402v1-max-250x250.png"],
             [[250,
               43],
              "assets/images/resized/0005/0402/50402v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Aperture Venture Partners",
         "permalink": "aperture-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               46],
              "assets/images/resized/0006/2293/62293v1-max-150x150.jpg"],
             [[208,
               65],
              "assets/images/resized/0006/2293/62293v1-max-250x250.jpg"],
             [[208,
               65],
              "assets/images/resized/0006/2293/62293v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Osage Venture Partners",
         "permalink": "osage-ventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BioAdvance",
         "permalink": "bioadvance",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0005/6697/56697v1-max-150x150.jpg"],
             [[226,
               66],
              "assets/images/resized/0005/6697/56697v1-max-250x250.jpg"],
             [[226,
               66],
              "assets/images/resized/0005/6697/56697v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "101 Lindenwood Drive",
    "address2": "Suite 400",
    "zip_code": "19355 ",
    "city": "Malvern",
    "state_code": "PA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        112],
       "assets/images/resized/0017/5337/175337v1-max-150x150.png"],
      [[250,
        188],
       "assets/images/resized/0017/5337/175337v1-max-250x250.png"],
      [[450,
        338],
       "assets/images/resized/0017/5337/175337v1-max-450x450.png"]],
    "attribution": null}],
 "external_links":
  []}